Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791403 | 1.00 | EGFR (0.65) | EGFRMAPTFBP1NPC1RAB9A | |
| SCHEMBL6799279 | 0.84 | MAPT (0.58) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL7830242 | 0.84 | MAPT (0.61) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL10812183 | 0.84 | MAPT (0.68) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL13515063 | 0.83 | MAPT (0.56) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL6796759 | 0.83 | MAPT (0.56) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL6802809 | 0.83 | MAPT (0.56) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL6803611 | 0.83 | MAPT (0.56) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL6799629 | 0.83 | MAPT (0.56) | EGFRMAPTNPC1RAB9ANFKB1 | |
| SCHEMBL6803308 | 0.83 | MAPT (0.56) | EGFRMAPTNPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4324896-B1 | DINUCLEAR PLATINUM(II) EMITTERS FOR RED AND/OR NEAR-INFRARED OLEDS | UNIV HONG KONG (HK) | 2025-05-14 | — | — | EP | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885MAPT 2459/4885FBP1 2622/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885MAPT 2459/4885FBP1 2622/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | EGFR 295/4885MAPT 1069/4885FBP1 3859/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885MAPT 2459/4885FBP1 2622/4885 |
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | EGFR 349/4885MAPT 1908/4885FBP1 1356/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885MAPT 2459/4885FBP1 2622/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | EGFR 378/4885MAPT 2213/4885FBP1 1244/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885MAPT 2459/4885FBP1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.